Prostate-specific antigen

Nanotechnology for prostate cancer Ming Gao NEU ID: 001983161 NNMD 5270 Introduction to Nanomedicine Science and Technology Professor Srinivas Sridhar Dr. Anne L. van de Ven Northeastern University 12/08/2014   Introduction Prostate cancer (PCa), the development of cancer in the prostate, is one of the most mortal diseases that threaten men’s lives in current world. It is the most commonly diagnosed non-skin cancer in the United States, and it is second leading cause of cancer deaths in

A prostate is a gland in the male reproductive system found below the bladder and in front of the rectum. Prostate cancer is cancer that forms in tissue in that gland, it usually occurs in older men. Cancer comes in forms of tumors, which is an abnormal growth of cells. Malignant tumors are the cancerous tumors of the two different types of tumors. Can cause pain and interfere with normal function, but they can also cause other systems in the body to act abnormally. Malignant tumors can invade nearby

Chemo-protective effects of cruciferous vegetables is comprehensively studied on intentions of reducing the onset of prostate cancer. Cruciferous vegetables contain many bioactive compounds. The anti-carcinogenic engagements of cruciferous vegetables are frequently related to the glucosinolate (sulfur-containing chemicals) component of these vegetables. The substrate components of glucosinolates are biologically active compounds that are being studied for possible anticancer effects in foods such

Prostate cancer is the most common type of carcinoma and the second leading cause of cancer death in men, following carcinoma of the lung. The risk of developing prostate cancer increases with age, beginning at age 50, and is also higher among African-American men. The two highest age subpopulations diagnosed are men 55-64 and 65-74 years of age, comprising 29.0% and 35.6% of all prostate cancer diagnoses, respectively. The age-adjusted incidence rate of prostate cancer is 159.3 per 100,000 men

A prostate is a gland in the male reproductive system found below the bladder and in front of the rectum. Prostate cancer is cancer that forms in tissue in that gland, it usually occurs in older men. Cancer comes in forms of tumors, which is an abnormal growth of cells. Malignant tumors are the cancerous tumors of the two different types of tumors. Can cause pain and interfere with normal function, but they can also cause other systems in the body to act abnormally. Malignant tumors can invade nearby

Prostate Cancer Prostate Cancer is a common type of cancer for men. It is cancer in a mans prostate which is a small walnut-sized gland that produces seminal fluid. From the standpoint of natural history and chance of progression in the individual patient, prostate cancer is one of the most variable of all tumors. The cancer itself may behave in a highly indolent matter and be localized in the prostate gland for years, with the patient’s death being due to other diseases. In 1853 J. Adams, who was

.2.1 Prostate Specific Antigen (PSA) PSA is a biomarker that is regularly used clinically for screening and diagnosis of prostate cancer. It was discovered in 1972 while trying to find a substance in seminal fluid that would aid in the research of medical cases. Papsidero and associates measured PSA quantitatively in the blood in 1980, which was stated to be a clinical use as a marker for prostate cancer. PSA exists in small quantities in the serum of normal men, and it is raised higher in the presence

The finding led to the belief that the solution lied in the saturation, where the maximal growth of the prostate cancer was achieved at a low level of testosterone. This model was produced by Fowler and Whitmore, who concluded “normal endogenous testosterone levels may be sufficient to cause near maximal stimulation of prostatic tumors.” There final conclusion was that “there is not today—nor has there ever been—a scientific basis for the contention that a higher T concentration causes pCA growth

The recommendation to reduce PSA screening by the Canadian Task Force of Preventative Health Care originated from the observations that PSA screening does not decrease the relative risk for acquiring PCa, nor does it decrease the mortality rate of PCa. Since the implementation of proactive and opportunistic PSA screening in Canada the annual incidence of PCa has increased but the mortality rate has not decreased (Pron, 2015). Ontario spends approximately $119.2 million on PSA screening annually

study, a comprehensive RALRP-specific learning curve has not been clearly defined 7-9.